View source for POLYCYSTIC KIDNEY DISEASE-TOLVAPTAN

===== [[Summary Article|'''SUMMARY''']] =====
1. Blocks V2 receptors in distal nephron and collection duct. In PCKD: reduce cysts formation.
<br/>
<br/>2. Prevents the binding of vasopressin, reduce expression of aquaporins.
<br/>
<br/>3. Promotes water excretion: polyuria and potential dehydration.
<br/>
<br/>4. Important to maintain adequate hydration to prevent activation of V1 receptors.


==Reference(s)==
Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. [https://amzn.to/3YHrI6K Get it on Amazon.]
<br/>Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. [https://amzn.to/3k7WSW0 Get it on Amazon.]
<br/>Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
<br/>Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].

[[Category:Polycystic Kidney Disease]]
[[Category:Nephrology]]
[[Category:Medicine]]